

Martin YEUNG

Research Assistant Professor



Qualifications:

Doctor of Philosophy (Ph.D.) The Hong Kong Polytechnic University, Hong Kong SAR, China	2022
M.Sc. in Biochemical and Biomedical Science The Chinese University of Hong Kong, Hong Kong SAR, China	2014
B.Sc. (Hons) in Biomedical Science Keele University, United Kingdom	2012

Brief Outline Of Relevant Experience And Posts Held:

Research Assistant Professor Department of Health Technology & Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China	08/2022 – Present
Research Associate Department of Health Technology & Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China	09/2021 – 07/2022
Associate Medical Technologist Prince of Wales Hospital, Sha Tin, Hong Kong SAR, China	2015 – 2018
Medical Laboratory Technologist II The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong SAR, China	2014 – 2015

Research Interests:

digital pathology; computational pathology; whole-slide imaging; artificial intelligence; histopathology; gastrointestinal tract; algorithms; machine learning; deep learning; cancer diagnosis, lipidomics; mass spectrometry imaging; obesity, chronic kidney disease; diabetic kidney disease; GLP-1R agonists; dulaglutide

Relevant Awards:

Final Stage in PolyU Student Entrepreneurial Proof-of-Concept (POC) Funding Scheme (Cohort 2), The Hong Kong Polytechnic University with HK\$5,000 cash prize	2022
Top 3 Teams in PolyU Student Entrepreneurial Proof-of-Concept (POC) Funding Scheme (Cohort 1), The Hong Kong Polytechnic University with HK\$15,000 cash prize	2022
Outstanding performance in oral presentation (3 rd prize) in Postgraduate Symposium 2021, HTI, PolyU	2021
Outstanding performance in oral presentation (2 nd prize) in Postgraduate Symposium 2020, HTI, PolyU	2020
Best Poster Presentation Award: Presented my Masters research findings at Lee Shau Kee Building, CUHK. Awarded to 3 out of 41 candidates.	2014

Publications:

ORCID: <https://orcid.org/0000-0001-8063-2929>

1. Pei XM[†], Yeung MHY[†], Wong, ANN, Tsang, HF, Yu ACS, Yim AKY and Wong SCC*. (2023) **Targeted Sequencing Approach and Its Clinical Applications for the Molecular Diagnosis of Human Diseases.** *Cells*, DOI: 10.3390/cells12030493 [IF: 7.666; Q1 – 40/274 (Biochemistry, Genetics and Molecular Biology)]
2. Wong ANN[†], He Z[†], Leung KL, To CCK, Wong CY, Chan AZ, Chan CKR, Lacambra MD, Yeung MHY* **Current Developments of Artificial Intelligence in Digital Pathology and its Future Clinical Applications in Gastrointestinal Cancers,** *Cancers*, DOI: 10.3390/cancers14153780 [IF: 6.575; Q1 – 172/369 (Oncology)]
3. Yeung MHY, Leung KL, Choi LY, Yoo JS, Yung S, So PK and Wong CM.* (2022) **Lipidomic Analysis Reveals the Protection Mechanism of GLP-1 Analogue Dulaglutide on High-Fat Diet-Induced Chronic Kidney Disease in Mice.** *Front. Pharmacol.* 12:777395. DOI: 10.3389/fphar.2021.777395 [IF: 5.988; Q1 – 38/265 (Medical Pharmacology)]
4. Leung HY, Yeung MHY, Leung WT, Wong KH, Tang WY, Cho WCS*, Wong HT, Tsang HF, Wong YKE, Pei XM, Cheng HYL, Chan AKC & Wong SCC* (2021) **The current and future applications of in situ hybridization technologies in Anatomical Pathology,** *Expert Review of Molecular Diagnostics*, 22:1, 5-18. DOI: 10.1080/14737159.2022.2007076 [IF: 5.670; Q1 – 40/204 (Pathology and Forensic Medicine)]
5. Xu L, Yeung MHY, Yau MYC, Lui PPY and Wong CM*. **Role of Histone Acetylation and Methylation in Obesity.** *Curr Pharmacol*, Rep 5, 196–203 (2019). DOI:10.1007/s40495-019-00176-7 [IF:1.524; Q2 – 140/316 (Pharmacology)]

Abstracts / Conferences:

1. **Yeung MHY***, Cheng GWY and Tse KH (2023), APOE-mediated lipid accumulation in endothelium – a pilot investigation of a common pathology in chronic kidney disease and age-related dementia. *The World Congress of Nephrology 2023*, Bangkok, Thailand, March 27 – April 2 2023
2. Tse K-H*, Wong W-M, Meng X-Y, Hui KHR, Wu LHD and **Yeung MHY** (2023), **Digital pathology-based histology education for medical scientists undergraduate program in Hong Kong (Abstract)**. *Pathology* **2023**, *55*, S77-S78, doi:10.1016/j.pathol.2022.12.257, The Journal of the Royal College of Pathologists of Australasia, Feb 2023
3. **Yeung MHY**, Leung KL, Choi LY, Yoo JS, Yung S, So PK and Wong CM* (2021), **Metabolomics analysis reveals the protection mechanism of GLP-1 analogue Dulaglutide on high-fat diet-induced chronic kidney disease in mice**. *The 11th International Congress of Diabetes and Metabolism (2021 ICDM) and 13th AASD Scientific Meeting*, Online, Oct 7 – 9 2021
4. Wong ANN*, **Yeung MHY***, Chan CKR, Chan AZ, Wong CY, Chan TYJ, Yoo JS and Wong CM (2021), **IDDF2021-ABS-0100 Prioritization on whole-slide images of clinical gastric carcinoma biopsies through a weakly supervised and annotation-free system [abstract]**. *Gut*, 70(Suppl 2), A122-A123. DOI:10.1136/gutjnl-2021-IDDF.137, International Digestive Disease Forum 2021, Sep 4 – 5 2021 [IF: 23.059; Q1 – 2/152 (Gastroenterology)]
5. **Yeung MHY**, So PK, Yoo JS, Wong CM* (2021) **Glucagon-like peptide 1 receptor agonist dulaglutide ameliorate kidney function in diet-induced obese mice by regulating lipids and metabolites**. *The 17th Annual Conference of the Metabolomics Society: METABOLOMICS 2021*, Online, June 22 – 24 2021
6. Lacambra MD*, Loong H, To KF, Feng X, Taylor G, Pleasance E, Laskin J, Marra M, Griffith J, **Yeung MHY**, Wong KC, Chow C, Kumta S, Ng WHA, Tse T, Tong C and Ng T (2018), **FUS-NFATc2 sarcoma of bone, a novel molecular entity with aggressive behavior: Clinical and molecular pathology findings of two cases**. *Ann. Oncol.* [IF: 32.976; Q1 – 7/369 (Oncology)]

Patents:

1. **Yeung HYM**, Wong NNA, Yoo JS, Chan CKR and To KF. US Provisional Patent Application (No. 63/366,019) for " Systems, methods and workflow for processing whole slide imaging for disease detection", Filed on 8 June 2022

Professional Affiliations:

- Medical Laboratory Technologist (MLT) Board Part I Registration, Hong Kong (Reg: MT103057)